| Followers | 71 |
| Posts | 10390 |
| Boards Moderated | 0 |
| Alias Born | 01/04/2007 |
Monday, August 10, 2020 11:03:47 AM
First of all it's "Repurposed" not "Repositioned".
Secondly Bucillamine was already repurposed for infectious disease. They were already planning to do flu trials. So it's not like they grabbed something off the shelf and said let's see if it sticks.
Revive isn't going to just blow millions of dollars for a phase 3 trial unless they have some idea that it works. Also with Dr. Boulware on the team, it's even more evident of it.
Secondly Bucillamine was already repurposed for infectious disease. They were already planning to do flu trials. So it's not like they grabbed something off the shelf and said let's see if it sticks.
Revive isn't going to just blow millions of dollars for a phase 3 trial unless they have some idea that it works. Also with Dr. Boulware on the team, it's even more evident of it.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
